The worldwide coronavirus pandemic has been one of the most significant health crisis
threats in recent years. COVID-19 has not been the only cause of mortality in this pandemic …

CAR T-cells have revolutionized the treatment of many hematological malignancies.
Thousands of patients with lymphoma, acute lymphoblastic leukemia, and multiple myeloma …

Abstract COVID‐19‐associated pulmonary aspergillosis (CAPA) remains a high mortality
mycotic infection throughout the pandemic, and glucocorticoids (GC) may be its root cause …

Background COVID-19, an emerging disease raised as a pandemic, urgently needed
treatment choices. Some options have been confirmed as lifesaving treatments, but long …

Introduction Polymorphonuclear cell influx into the interstitial and bronchoalveolar spaces is
a cardinal feature of severe coronavirus disease 2019 (COVID-19), principally mediated by …

Objective: Rare coexistence of disease or pathology Background: The management of
(Coronavirus disease 2019) COVID-19 pneumonia is ever-evolving. Tocilizumab, a …

Systemic hyperinflammation is a hallmark of severe coronavirus disease-2019 (COVID-19).
Tocilizumab (TCZ)(an interleukin-6 receptor blocker) therapy is currently used as an anti …

Background Selection of effective and safe therapy for management of patients with
coronavirus disease is challenging. Tocilizumab (TZB) has emerged as a potential treatment …

We aimed to assess the factors associated with mortality in patients treated with tocilizumab
for a SARS-CoV-2 pneumonia due to the delta or omicron variants of concern (VOC) and …

Abstract Purpose of Review The landscape of the coronavirus disease 2019 (COVID-19)
pandemic has rapidly changed over the past 3 years. Paralleling this evolution, the scientific …